For those following the health-care sector, there's no doubt that 2013 will be known as the year of the spinoff. However, the year started out with rampant speculation that another big acquisition was in the cards -- private equity firm Warburg Pincus was looking for a liquidity event for eye-care specialist Bausch & Lomb.
The potential price: $10 billion. The potential suitors: Abbott Labs , Johnson & Johnson , Merck , Pfizer , and Sanofi . Follow along in the video below as Brenton Flynn runs through the likely final result.
Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy, and a year of free analyst updates, by clicking here now.
The article Left at the Altar: No Buyout for This Health-Care Giant originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.